A rapidly changing biotech industry requires research efforts as much as it does state-of-the-art equipment and reagents. ACROBiosystems is committed to providing high purity, customizable, and bioactive reagents to support research and translation in cancer immune therapy. Their catalogue ranges in targets for various diseases including COVID-19, immune-oncology, inflammatory diseases, and recently neurobiology.
In addition to these targets, ACROBiosystems develop difficult-to-express targets such as full-length transmembrane proteins, virus-like particles, and detergent micelles.
During this talk we cover:- The development of co-culture disease models
- Co-culture disease models and their relevance in drug screening
